Loading
The neuroblastoma response criteria combine the primary tumour, any spread to bone or soft tissue, and the bone marrow into one overall response for a child's treatment.
The 2017 revision (Park and colleagues, Journal of Clinical Oncology), from an NCI clinical trials planning meeting with investigators from 13 countries, integrates response in the primary tumour, soft tissue and bone metastases, and bone marrow. Soft tissue sites are assessed with RECIST and MIBG scans, or FDG PET if the tumour does not take up MIBG; MIBG or FDG PET replaces bone scintigraphy for bone disease; marrow is assessed by histology and cytology, with 5% or less involvement classed as minimal disease; urinary catecholamines are no longer used. Overall response is complete, partial, minor, stable or progressive.
Showing the technology this term belongs to: MIBG imaging and 131I-MIBG therapy.
Shares MIBG Curie and SIOPEN scores, MIBG imaging and 131I-MIBG therapy, Neuroblastoma (paediatric).
Shares MIBG Curie and SIOPEN scores, MIBG imaging and 131I-MIBG therapy, Neuroblastoma (paediatric).
Shares MIBG Curie and SIOPEN scores, Neuroblastoma (paediatric).
Shares MIBG imaging and 131I-MIBG therapy, Neuroblastoma (paediatric).
Shares MIBG imaging and 131I-MIBG therapy, Neuroblastoma (paediatric).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/